Bristol Myers Squibb in collaboration with Janssen Pharmaceuticals announced all three prospective antithrombotic indications for milvexian have received fast track designation from the FDA. The designation covers all three phase 3 Librexia development studies of the investigational oral factor XIa inhibitor: Librexia Stroke, Librexia ACS and Librexia AF. According to a company press release, the